https://pubmed.ncbi.nlm.nih.gov/39590800/

Marine fungi produce bioactive lipids with anti-inflammatory, antioxidant, and antithrombotic properties, showing health benefits, though their potential remains underexplored due to limited marine mycology expertise.

https://pubmed.ncbi.nlm.nih.gov/39325368/

Picky eating complicates dyslipidemia management in children; providers should validate concerns, screen behavior, guide families, and refer specialists, emphasizing heart-healthy, child-friendly dietary strategies and resources.

Marine phytoplankton produces bioactive lipids with immunomodulatory properties, resembling eicosanoids and prostaglandins. Genetic engineering and optimized cultivation can enhance yields, supporting therapeutic applications for chronic inflammation and other clinical conditions.

Exosomal lipids play a crucial role in cancer metastasis by influencing signaling pathways, immunomodulation, and energy production. Understanding their function may provide insights into novel strategies to combat cancer progression.

This review explores lipids' roles in clinical nutrition, emphasizing their impact on chronic disease prevention, dietary recommendations, and emerging lipid-based therapies for managing cardiovascular disease, obesity, and metabolic syndrome.

This review highlights challenges in achieving LDL-C targets for cardiovascular prevention, emphasizing the underuse of high-intensity statins and advocating for moderate-intensity statins plus ezetimibe as an effective alternative strategy.

A 12-week RCT found that time-restricted feeding (16/8) with a Lacto-Ovo-Vegetarian diet significantly improved weight, metabolic markers, liver health, and lipid profiles in overweight and obese patients with MAFLD.

This review explores the interplay of functional foods, gut microbiota, and nutrigenomics in managing diabetes and obesity, emphasizing personalized nutrition strategies for metabolic health and advocating further clinical validation.

Dietary anthocyanins improve HDL-C, triglycerides, and glycemic markers in MetS but show minimal effects on obesity and blood pressure. Further large-scale trials are needed to confirm long-term efficacy and safety.

Statins and PCSK-9 inhibitors were not associated with a significant increased risk of intracerebral hemorrhage. Network meta-analysis confirms their safety, though further studies are needed for validation.

Dyslipidemia, a key cardiovascular risk, is managed through lifestyle changes and lipid-lowering drugs like statins, fibrates, PCSK9 inhibitors, and bempedoic acid. Further trials are needed to assess efficacy and safety.

Dyslipidemia significantly influences stroke risk, with varying impacts across stroke subtypes. This study examines lipid-lowering therapies like statins, ezetimibe, and PCSK9 inhibitors for secondary stroke prevention and dyslipidemia management.

Optimizing lipid management requires multidisciplinary care, patient adherence strategies, EHR utilization, telehealth, and systematic approaches targeting clinicians, patients, and systems, with future research focusing on long-term outcomes, sustainability, and scalability.

Elevated Atherogenic Index of Plasma (AIP) significantly predicts major cardiovascular events, myocardial infarction, cardiovascular death, and revascularization in coronary artery disease, highlighting its prognostic value and potential for targeted interventions.

Palmitic acid (PA)-induced lipotoxicity in obesity and MetS involves ER stress, mitochondrial dysfunction, and ROS. Protective mechanisms include FFAR activation, lipid droplet storage, and antioxidants to counteract oxidative damage and dysfunction.

Lipotoxicity in ischemic acute kidney injury involves lipid accumulation and mitochondrial dysfunction. A novel "immunometabolic" lipotoxicity mechanism is explored, highlighting potential therapeutic strategies using lipid-lowering medications to mitigate kidney damage.

Supersaturable SMEDDS enhance bioavailability of poorly soluble drugs by maintaining supersaturation using polymers like hypromellose. This approach enables smaller doses, reduced GI irritation, and improved pediatric and elderly formulations.

A meta-analysis of 15 studies (1708 patients) found that letrozole and exemestane negatively impact lipid profiles in postmenopausal breast cancer patients, warranting monitoring, especially in those with cardiovascular risk factors.

Lipids play critical roles in brain function and may serve as blood biomarkers for mental illnesses, though further research is needed to clarify their diagnostic potential and effects of psychiatric medications.

The ORION-8 study demonstrated that long-term inclisiran use consistently lowered LDL-C by 49.4% with 78.4% achieving LDL-C goals, showing favorable safety and tolerability over 12,000+ patient-years exposure.